CU24609B1 - Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic - Google Patents
Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de micInfo
- Publication number
- CU24609B1 CU24609B1 CU2018000050A CU20180050A CU24609B1 CU 24609 B1 CU24609 B1 CU 24609B1 CU 2018000050 A CU2018000050 A CU 2018000050A CU 20180050 A CU20180050 A CU 20180050A CU 24609 B1 CU24609 B1 CU 24609B1
- Authority
- CU
- Cuba
- Prior art keywords
- protein
- domain
- ferritin subunit
- fusion protein
- linked
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 101710157275 Ferritin subunit Proteins 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263377P | 2015-12-04 | 2015-12-04 | |
| US201662422454P | 2016-11-15 | 2016-11-15 | |
| PCT/US2016/064969 WO2017096374A1 (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180050A7 CU20180050A7 (es) | 2018-11-06 |
| CU24609B1 true CU24609B1 (es) | 2022-06-06 |
Family
ID=57590885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000050A CU24609B1 (es) | 2015-12-04 | 2016-12-05 | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic |
| CU2021000061A CU20210061A7 (es) | 2015-12-04 | 2016-12-05 | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000061A CU20210061A7 (es) | 2015-12-04 | 2016-12-05 | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10993971B2 (https=) |
| EP (1) | EP3383426A1 (https=) |
| JP (3) | JP7099956B2 (https=) |
| KR (1) | KR20180088458A (https=) |
| CN (1) | CN108770343A (https=) |
| AU (3) | AU2016362597C1 (https=) |
| BR (1) | BR112018010705A8 (https=) |
| CA (1) | CA3005910A1 (https=) |
| CL (3) | CL2018001470A1 (https=) |
| CO (1) | CO2018006642A2 (https=) |
| CR (2) | CR20180350A (https=) |
| CU (2) | CU24609B1 (https=) |
| EA (1) | EA201891287A1 (https=) |
| IL (1) | IL259490A (https=) |
| MX (2) | MX2018006785A (https=) |
| MY (1) | MY199248A (https=) |
| NZ (1) | NZ742663A (https=) |
| PE (2) | PE20230495A1 (https=) |
| PH (1) | PH12018501170A1 (https=) |
| RU (2) | RU2747296C2 (https=) |
| SG (1) | SG11201804597TA (https=) |
| TN (1) | TN2018000187A1 (https=) |
| WO (1) | WO2017096374A1 (https=) |
| ZA (1) | ZA202204223B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| BR112020019938A2 (pt) | 2018-04-03 | 2021-01-26 | Sanofi | polipeptídeos antigênicos de vírus sincicial respiratório |
| CN112512564A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 铁蛋白蛋白 |
| CA3095174A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic ospa polypeptides |
| US20240207385A1 (en) * | 2020-02-26 | 2024-06-27 | The Wistar Institute Of Anatomy And Biology | Compositions comprising self-assembling vaccines and methods of using the same |
| CA3184940A1 (en) | 2020-07-07 | 2022-01-13 | Jennifer Donglan WU | Mic antibodies and binding agents and methods of using the same |
| CN116396398B (zh) * | 2023-01-16 | 2024-07-16 | 四川大学 | 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台 |
| CN121620389A (zh) * | 2023-04-28 | 2026-03-06 | 先为(海南)生物科技有限公司 | 一种针对MICA/B靶点的mRNA肿瘤疫苗 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| EP0643559B1 (en) | 1992-05-06 | 1999-04-14 | The President And Fellows Of Harvard College | Diphtheria toxin receptor-binding region |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| JP4469026B2 (ja) | 1996-10-31 | 2010-05-26 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| ES2275499T3 (es) | 1999-03-19 | 2007-06-16 | Glaxosmithkline Biologicals S.A. | Vacuna contra streptococcus pneumoniae. |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| WO2003028632A2 (en) | 2001-10-01 | 2003-04-10 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Development of a preventive vaccine for filovirus infection in primates |
| US6706305B2 (en) | 2001-10-31 | 2004-03-16 | Conagra Foods Inc. | Low glycemic index bread |
| EP1504037B1 (en) | 2002-05-10 | 2009-12-30 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| JP5525689B2 (ja) | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| CA2665090A1 (en) | 2006-09-22 | 2008-03-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating mica-related disorders |
| US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
| WO2011046842A1 (en) | 2009-10-12 | 2011-04-21 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| US8889044B2 (en) | 2009-12-18 | 2014-11-18 | Kao Corporation | Method for producing mesoporous silica particles |
| JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
| RU2489169C2 (ru) * | 2010-10-12 | 2013-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Способ лечения онкологических заболеваний |
| EP2758072A1 (en) * | 2011-09-23 | 2014-07-30 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| ES2925654T3 (es) | 2011-09-30 | 2022-10-19 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
| EP2812027A1 (en) * | 2012-02-07 | 2014-12-17 | Innate Pharma | Mica binding agents |
| CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
| JP6518199B6 (ja) * | 2013-03-15 | 2019-06-12 | ノヴェロジックス・バイオテクノロジー，インコーポレーテッド | Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体 |
| KR20150130462A (ko) | 2013-03-15 | 2015-11-23 | 다나-파버 캔서 인스티튜트 인크. | 치료 펩티드 |
| WO2015139020A2 (en) * | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
-
2016
- 2016-12-05 KR KR1020187019140A patent/KR20180088458A/ko not_active Ceased
- 2016-12-05 CR CR20180350A patent/CR20180350A/es unknown
- 2016-12-05 MY MYPI2018000849A patent/MY199248A/en unknown
- 2016-12-05 RU RU2018123307A patent/RU2747296C2/ru active
- 2016-12-05 CA CA3005910A patent/CA3005910A1/en active Pending
- 2016-12-05 BR BR112018010705A patent/BR112018010705A8/pt active Search and Examination
- 2016-12-05 NZ NZ742663A patent/NZ742663A/en unknown
- 2016-12-05 WO PCT/US2016/064969 patent/WO2017096374A1/en not_active Ceased
- 2016-12-05 CU CU2018000050A patent/CU24609B1/es unknown
- 2016-12-05 CU CU2021000061A patent/CU20210061A7/es unknown
- 2016-12-05 AU AU2016362597A patent/AU2016362597C1/en active Active
- 2016-12-05 MX MX2018006785A patent/MX2018006785A/es unknown
- 2016-12-05 SG SG11201804597TA patent/SG11201804597TA/en unknown
- 2016-12-05 PE PE2022002801A patent/PE20230495A1/es unknown
- 2016-12-05 PE PE2018001072A patent/PE20181158A1/es unknown
- 2016-12-05 US US15/781,448 patent/US10993971B2/en active Active
- 2016-12-05 JP JP2018528691A patent/JP7099956B2/ja active Active
- 2016-12-05 CN CN201680080434.4A patent/CN108770343A/zh active Pending
- 2016-12-05 EP EP16816550.4A patent/EP3383426A1/en active Pending
- 2016-12-05 RU RU2021109510A patent/RU2021109510A/ru unknown
- 2016-12-05 TN TNP/2018/000187A patent/TN2018000187A1/en unknown
- 2016-12-05 CR CR20230116A patent/CR20230116A/es unknown
- 2016-12-05 EA EA201891287A patent/EA201891287A1/ru unknown
-
2018
- 2018-05-21 IL IL259490A patent/IL259490A/en unknown
- 2018-06-01 MX MX2022010194A patent/MX2022010194A/es unknown
- 2018-06-01 CL CL2018001470A patent/CL2018001470A1/es unknown
- 2018-06-01 PH PH12018501170A patent/PH12018501170A1/en unknown
- 2018-06-27 CO CONC2018/0006642A patent/CO2018006642A2/es unknown
-
2021
- 2021-02-19 US US17/180,183 patent/US20210299186A1/en not_active Abandoned
- 2021-05-13 CL CL2021001256A patent/CL2021001256A1/es unknown
-
2022
- 2022-03-21 AU AU2022201940A patent/AU2022201940B2/en active Active
- 2022-04-14 ZA ZA2022/04223A patent/ZA202204223B/en unknown
- 2022-06-30 JP JP2022105405A patent/JP7564842B2/ja active Active
-
2023
- 2023-10-26 CL CL2023003217A patent/CL2023003217A1/es unknown
-
2024
- 2024-02-19 US US18/581,148 patent/US20250064863A1/en active Pending
- 2024-09-27 JP JP2024167997A patent/JP2024177207A/ja active Pending
-
2025
- 2025-08-08 AU AU2025213685A patent/AU2025213685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24609B1 (es) | Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic | |
| EP4442816A3 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| CO2018000303A2 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| PE20181354A1 (es) | Mutantes de proteina f de rsv | |
| MX394191B (es) | Composiciones para el cuidado bucal y metodos de uso | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| EA201491049A1 (ru) | Противораковый слитый белок | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| PE20151978A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| AR132574A2 (es) | UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| MX420767B (es) | Proteina de union al factor h modificada |